Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Purple Biotech ( (PPBT) ) has provided an announcement.
On September 4, 2025, Purple Biotech announced new data supporting the unique design of its CAPTN-3 tri-specific antibody IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai. The data, presented by Dr. Amir Horowitz, showed that IM1240 induces tumor cell death in treatment-resistant head and neck cancer biopsies, with synergistic effects observed between its NK and T cell engager arms. This advancement is significant as it supports the design of IM1240, which targets the novel tumor-associated antigen 5T4, and moves towards first-in-human clinical trials with an IND submission planned for 2026. The findings highlight the potential of IM1240 as a safer and more effective immunotherapeutic strategy, enhancing Purple Biotech’s position in the oncology field.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Its oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies designed to engage T cells and NK cells to induce a localized immune response within the tumor microenvironment. The company is headquartered in Rehovot, Israel.
Average Trading Volume: 112,267
Technical Sentiment Signal: Sell
Current Market Cap: $5.59M
See more data about PPBT stock on TipRanks’ Stock Analysis page.